PLOS ONE | DOI:10.1371/journal.pone.0142290 November 9, 2015; 1 / 16
Review
S Afr Med J 2014;104(3):174-177. DOI: 10.7196/SAMJ.7968
Guidelines for Management and Treatment of Dyslipidemia in Indonesia
Guidelines for Treatment and Management of Heart Failure in Indonesia
Guidelines and Consensus for the Diagnosis, Management and Prevention of Type 2 Diabetes Mellitus in Indonesia
JIMSA Jan.-March 2015 Vol. 28 no.1 p.47-50e
The Guide
Ratgeber Parkinson – Englisch
Accessed: 11.03.2019
PLoSONE 12(9):e0184986.https://doi.org/10.1371/journal.pone.0184986
In resource-limited countries, the number of available antiretroviral (ARV) drugs is relatively limited. Hence, caregivers face some caution and constraints in the changes of ARV treatment (ART) in people living with HIV (PLHIV). Our objective was to calculate the incidence, to describe the main cau...ses and to identify the predictive factors of the first change of ARV treatment in Senegal.
more
Published: April 26, 2017 https://doi.org/10.1371/journal.pone.0176004
doi: https://doi.org/10.1101/2020.11.30.20236570
Pre-Print Article
Data on Infectious Diseases in Ukraine Now Available as a Free eBook to Help Medics and Relief Efforts During the War.
• Data on the 215+ infectious diseases endemic to Ukraine
• All published data on infections imported into Ukraine
To download the book, please click the button below and use... the coupon code EBOOKUKRAINE at checkout: The code will expire in 30 days.
March 2nd, 2022
more
May 9, 2022.Since the onset of the COVID-19 pandemic, a large number of clinical trials have been planned and developed to assess the effectiveness and safety of various interventions that could prevent hospitalizations and progression to severe disease in people infected with SARS-CoV-2. Currently,... the WHO and the PAHO recommend the use of corticosteroids, tocilizumab, baricitinib, and casirivimab e imdevimab (the latter in seronegative COVID-19 patients) and propose the use of sotrovimab, casirivimab/imdevimab, and molnupiravir in patients with non-severe illness who are at high risk for complications
more
Since the discovery of insulin nearly 100 years ago, advances in diabetes treatments and therapies have transformed the lives of people
with diabetes (PwD), notably reducing the daily burden of its management.
Newer technologies, including those driven by artificial intelligence, have the potentia...l to further improve the quality of life of PwD and help
identify and diagnose people at risk of developing Type 2 diabetes and diabetes-related complications early. However, medical and technological advances alone are not enough to fix the diabetes challenge. It is also critical to acknowledge the complexity and the seriousness of diabetes, its impact on the quality of life and well-being of over 32 million PwD in the EU and the financial burden it represents for health systems and society at large.
more